Mastodon

Bystrum Forte (Gel) Instructions for Use

ATC Code

M02AA10 (Ketoprofen)

Active Substance

Ketoprofen (Rec.INN registered by WHO)

Clinical-Pharmacological Group

NSAIDs for external use

Pharmacotherapeutic Group

Drugs for external use for muscle and joint pain; non-steroidal anti-inflammatory drugs for external use

Pharmacological Action

NSAID. It has analgesic, anti-inflammatory, and anti-edematous effects. It inhibits the activity of COX, which leads to the suppression of prostaglandin synthesis.

In addition, Ketoprofen inhibits lipoxygenase, bradykinin synthesis, stabilizes lysosomal membranes, and prevents the release of enzymes involved in the inflammatory process.

Ketoprofen does not have a negative effect on the condition of the articular cartilage.

Pharmacokinetics

Ketoprofen is absorbed very slowly and practically does not accumulate in the body. Bioavailability is 5%.

Ketoprofen penetrates into the subcutaneous tissue, ligaments and muscles, synovial fluid and reaches therapeutic concentrations there. The concentration of the drug in blood plasma is extremely low.

Ketoprofen is metabolized in the liver to form conjugates, which are mainly excreted in the urine. Ketoprofen is characterized by slow excretion in the urine.

Indications

Symptomatic therapy of painful and inflammatory processes of various origins, including: rheumatoid arthritis and periarthritis; ankylosing spondylitis (Bekhterev’s disease); psoriatic arthritis; reactive arthritis (Reiter’s syndrome); osteoarthritis of various locations; tendinitis, bursitis; myalgia; neuralgia; radiculitis; injuries of the musculoskeletal system (including sports), muscle and ligament bruises, sprains, ruptures of ligaments and muscle tendons.

ICD codes

ICD-10 code Indication
M02.3 Reiter's disease
M05 Seropositive rheumatoid arthritis
M07 Psoriatic and enteropathic arthropathies
M15 Polyosteoarthritis
M19.9 Unspecified arthrosis
M42 Spinal osteochondrosis
M45 Ankylosing spondylitis
M47 Spondylosis
M54.1 Radiculopathy
M54.3 Sciatica
M54.4 Lumbago with sciatica
M65 Synovitis and tenosynovitis
M70 Soft tissue disorders related to use, overuse, and pressure
M71 Other bursopathies
M75.0 Adhesive capsulitis of shoulder
M79.1 Myalgia
M79.2 Neuralgia and neuritis, unspecified
T14.0 Superficial injury of unspecified body region (including abrasion, bruise, contusion, hematoma, bite of nonvenomous insect)
T14.3 Dislocation, sprain and strain of joint and ligament of unspecified body region
ICD-11 code Indication
8B93.Z Radiculopathy, unspecified
8E4A.1 Paraneoplastic or autoimmune diseases of the peripheral or autonomic nervous system
EH92 Dermatoses provoked by friction or mechanical impact
EH92.1 Blister due to friction
FA05 Polyosteoarthritis
FA0Z Osteoarthritis, unspecified
FA11.2 Arthropathy following genitourinary system infection
FA20.0 Seropositive rheumatoid arthritis
FA21.Z Psoriatic arthritis, unspecified
FA85.Z Defects of vertebral end-plates, unspecified
FA8Z Degenerative disease of spine, unspecified
FA92.0Z Ankylosing spondylitis, unspecified
FB40.Z Tenosynovitis, unspecified
FB50.1 Bursitis associated with use, overuse or pressure
FB50.Z Bursitis, unspecified
FB53.0 Adhesive capsulitis of shoulder
FB56 Specified soft tissue diseases, not elsewhere classified
FB56.2 Myalgia
ME84.20 Lumbago with sciatica
ME84.3 Sciatica
ND56.0 Superficial injury of unspecified body region
ND56.3 Dislocation, sprain or strain of unspecified body region

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Apply a sufficient amount of gel to the affected area 2 to 3 times daily.

Gently rub the gel into the skin until fully absorbed.

Wash hands thoroughly after each application unless the hands are the treated area.

The maximum duration of self-treatment without consulting a physician is 14 days.

Do not exceed a treated surface area of 10% of the total body surface.

For combination therapy with oral forms, ensure the total daily dose from all formulations does not exceed 200 mg of ketoprofen.

Strictly avoid contact with eyes, mucous membranes, and open or infected wounds.

Do not apply under occlusive dressings.

Protect treated skin from sunlight and UV radiation (including solariums) during treatment and for two weeks after the last application.

Discontinue use and consult a physician if no improvement is observed within the recommended treatment period or if symptoms worsen.

Adverse Reactions

Allergic reactions: very rarely – angioedema, anaphylaxis.

Skin and subcutaneous tissue disorders: infrequently – erythema, itching, burning, eczema, transient mild dermatitis; rarely – urticaria, rash, photosensitivity, bullous dermatitis, purpura, erythema multiforme, lichenoid dermatitis, skin necrosis, Stevens-Johnson syndrome; very rarely – isolated case of severe contact dermatitis (against the background of poor hygiene and insolation), isolated case of severe generalized photodermatitis, toxic epidermal necrolysis.

Respiratory system disorders: very rarely – asthmatic attacks (as a variant of an allergic reaction).

Urinary system disorders: very rarely – deterioration of renal function in patients with chronic renal failure.

Contraindications

Hypersensitivity to ketoprofen; hypersensitivity to salicylates, tiaprofenic acid or other NSAIDs, to fenofibrate, UV blockers, fragrances; violation of the integrity of the skin (eczema, weeping dermatitis, open or infected wound); history of bronchial asthma attacks caused by taking NSAIDs and salicylates; history of photosensitivity reactions; exposure to sunlight, including indirect sunlight and UV radiation in a solarium throughout the entire treatment period and for another 2 weeks after cessation of treatment; third trimester of pregnancy; children under 15 years of age.

With caution

Impaired liver and/or kidney function, erosive and ulcerative lesions of the gastrointestinal tract, blood diseases, bronchial asthma, chronic heart failure.

Use in Pregnancy and Lactation

Use is contraindicated in the third trimester of pregnancy. Use in the first and second trimesters is possible in cases where the expected benefit of therapy for the mother outweighs the potential risk to the fetus.

Use during lactation (breastfeeding) is not recommended.

Use in Hepatic Impairment

Should be used with caution in case of impaired liver function.

Use in Renal Impairment

Should be used with caution in case of impaired renal function.

Pediatric Use

Contraindication: children under 15 years of age.

Geriatric Use

Use with caution in elderly patients.

Special Precautions

Avoid getting this product into the eyes, on the skin around the eyes, and on mucous membranes.

Ketoprofen can be used externally in combination with oral administration. The total daily dose, regardless of the dosage form, should not exceed 200 mg.

To reduce the risk of developing photosensitivity, it is recommended to protect skin areas treated with ketoprofen with clothing from exposure to UV radiation throughout the entire treatment period and for another 2 weeks after stopping the use of the gel.

Do not use with occlusive dressings.

Drug Interactions

Since the concentration of ketoprofen in blood plasma is extremely low, manifestations of interaction symptoms with other drugs (similar to symptoms with systemic use) are possible only with frequent and long-term use.

Concomitant use of other topical agents containing Ketoprofen or other NSAIDs is not recommended.

Concomitant administration of acetylsalicylic acid reduces the degree of binding of ketoprofen to plasma proteins.

Ketoprofen reduces the excretion of methotrexate and contributes to an increase in its toxicity.

Patients taking coumarin-containing anticoagulants are recommended to undergo treatment under medical supervision.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Over-the-Counter

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

Brand (or Active Substance), Marketing Authorisation Holder, Dosage Form

Marketing Authorization Holder

Medana Pharma, SA (Poland)

Dosage Form

Bottle OTC Icon Bystrum Forte Gel for external use 5%: tubes 30 g, 50 g, or 100 g

Dosage Form, Packaging, and Composition

Gel for external use from colorless to yellow, homogeneous.

1 g
Ketoprofen lysine 50 mg

Excipients: carbomer (type 980 NF), ethanol 96%, polysorbate-80, trolamine, methylparahydroxybenzoate, purified water.

30 g – aluminum tubes (1) – cardboard packs.
50 g – aluminum tubes (1) – cardboard packs.
100 g – aluminum tubes (1) – cardboard packs.

Marketing Authorization Holder

Polpharma, S.A. (Poland)

Dosage Form

Bottle OTC Icon Bystrum Forte Gel for external use 5%: tubes 30 g, 50 g, or 100 g

Dosage Form, Packaging, and Composition

Gel for external use from colorless to yellow, homogeneous.

1 g
Ketoprofen lysine 50 mg

Excipients: carbomer (type 980 NF), ethanol 96%, polysorbate-80, trolamine, methylparahydroxybenzoate (E218), purified water.

30 g – aluminum tubes (1) – cardboard packs.
50 g – aluminum tubes (1) – cardboard packs.
100 g – aluminum tubes (1) – cardboard packs.

TABLE OF CONTENTS